Fertility Tourism: When Women Cross Borders for Reproductive Autonomy

The Global Fertility Market

The global fertility industry is estimated to be worth over $30 billion, and a significant and growing portion of that revenue comes from cross-border patients. Women travel from the UK to Spain for IVF. From Australia to Thailand for egg freezing. From Ireland to Ukraine for surrogacy. From Nigeria to South Africa for fertility treatments unavailable or unaffordable at home.

The drivers are varied: cost, legal restrictions, wait times, quality of care, and the simple fact that reproductive technology is unevenly distributed across the globe. For many women, crossing a border is not a lifestyle choice. It is the only way to access the care they need.

Fertility tourism is the market's answer to a problem that should never have existed: the unequal distribution of reproductive healthcare.

The Cost Calculus

In the United Kingdom, a single cycle of IVF costs approximately £5,000 to £8,000 privately. The NHS provides up to three cycles, but eligibility criteria have been tightened so severely that many women do not qualify. In Spain, the same treatment costs €3,000 to €5,000, and clinics are accustomed to treating international patients.

In India, IVF costs between ₹1,00,000 and ₹3,00,000 — far less than in the West, but a significant sum in a country where the median annual income is approximately ₹3,00,000. Indian IVF clinics have begun marketing to international patients, particularly from Africa, the Middle East, and Southeast Asia, offering treatment at a fraction of Western prices.

The cost disparity drives the fertility tourism industry. A woman who cannot afford treatment in her home country can often afford it elsewhere. The economics are straightforward; the ethics are not.

The fertility market operates on the same logic as every other global market: those with resources travel to where the cheapest, best treatment is available. Those without resources go without.

The Legal Landscape

Legal restrictions are one of the most significant drivers of fertility tourism. In Germany, egg donation is illegal. In Italy, both egg and sperm donation are prohibited. In many countries in the Middle East and parts of South Asia, IVF is available only to married heterosexual couples.

For women who fall outside these restrictions — single women, same-sex couples, women of advanced maternal age, women who want to freeze their eggs as a precaution — crossing a border may be the only option. The rise of egg freezing has been particularly significant. In countries where egg freezing is restricted or unavailable, women travel to clinics in Spain, Greece, or the Czech Republic to preserve their fertility.

In India, the Assisted Reproductive Technology Regulation Act of 2021 introduced regulations that effectively banned egg freezing for single women and restricted IVF access to married heterosexual couples. The Act also banned commercial surrogacy, which had made India a major destination for international surrogacy tourism.

The law tells women what they can and cannot do with their own eggs. The market tells them where to go to do it anyway.

The Indian Context

India has long been a destination for fertility tourism. The country's large network of fertility clinics, relatively low costs, and permissive regulatory environment (prior to 2021) attracted patients from across the world. Surrogacy tourism, in particular, brought thousands of international couples to Indian clinics, where surrogate mothers — predominantly from lower-income backgrounds — carried pregnancies for a fraction of the cost of surrogacy in the US or Europe.

The 2021 regulation ended commercial surrogacy, but the fertility tourism industry has adapted. Indian clinics now market IVF, egg donation, and genetic testing to international patients. The patients have changed too: rather than Western couples seeking surrogates, the new fertility tourists are women from Southeast Asia, Africa, and the Middle East seeking affordable IVF.

For Indian women, the picture is more complex. Urban, educated women with financial resources increasingly freeze their eggs — a practice that has gained cultural visibility in recent years, aided by celebrity endorsements and media coverage. But access remains deeply unequal. An upper-middle-class woman in Mumbai can freeze her eggs at a private clinic; a woman in rural Madhya Pradesh cannot even access basic fertility assessment.

Egg freezing in India is a class marker. The ability to plan your fertility on your own timeline is a privilege, not a right.

The Ethics of Cross-Border Care

Fertility tourism raises significant ethical questions. When women travel for treatment, they leave behind the regulatory frameworks, patient protection systems, and legal recourse mechanisms of their home countries. The standards of care in destination clinics vary widely. The quality of information provided to patients is inconsistent.

In some cases, the power imbalance is extreme. A woman who travels from a low-income country to a high-income one for treatment is vulnerable — she may not speak the language, she may not understand the legal framework, she may have limited access to recourse if something goes wrong.

The commercial surrogacy industry in India, before its ban, illustrated these dynamics at their most stark. Surrogate mothers — overwhelmingly from impoverished backgrounds — carried pregnancies for international couples under conditions that critics described as exploitative. The economic desperation of the surrogates was the engine of the industry.

Surrogacy tourism was not reproductive choice. It was reproductive outsourcing, built on the poverty of women who had no other options.

The Emotional Cost

Beyond the physical and financial dimensions, fertility tourism carries a significant emotional burden. Women who travel for treatment are often doing so alone, or with a partner who may not fully share the emotional weight of the journey. They are navigating unfamiliar medical systems, making decisions in a language that may not be their own, and managing the physical demands of treatment far from home.

The isolation is compounded by secrecy. Many women do not tell friends or family about their fertility treatment, let alone that they are travelling abroad for it. The shame surrounding infertility — which remains intense in Indian culture — ensures that the emotional cost is borne privately.

She sits alone in a clinic in a country she has never visited, waiting for a procedure that will determine whether she becomes a mother. No one at home knows she is here.

What the Market Cannot Solve

Fertility tourism is a symptom of a deeper problem: the global distribution of reproductive healthcare is fundamentally unequal. The market, left to its own devices, will continue to produce these disparities — making treatment available to those who can travel and pay, and inaccessible to those who cannot.

What is needed is not a better fertility tourism industry but a more equitable distribution of fertility care. This means investment in reproductive healthcare in low- and middle-income countries, regulation that ensures quality and access, and a willingness to confront the economic and social structures that determine who can and cannot reproduce on their own terms.

The question is not why women travel for fertility treatment. The question is why the world has made it necessary.